|
WO2021048285A1
|
|
Medicinal preparation for treating fibrosis with anti bsp antibodies
|
|
WO2020165456A1
|
|
Rapid test for diagnosis of bacterial infections in neonates
|
|
WO2020094880A2
|
|
Bone sialoprotein functionalized materials for directed bone regeneration
|
|
EP3629017A1
|
|
Pickup-safe stool collection tube
|
|
WO2020038954A1
|
|
Sorbent composition for pre-analytical treatment of samples
|
|
WO2019215199A1
|
|
System for analysing quantitative lateral flow chromatography
|
|
WO2019141791A1
|
|
Biomarker predicting coronary artery disease
|
|
EP3735591A1
|
|
Method of measuring the endocytic vitamin d status
|
|
WO2018224548A1
|
|
Point-of-care testing of pro-thymosin 100-109 for detecting sepsis
|
|
WO2018206772A1
|
|
Method and test instruments for quantitatively determining biomarkers in faecal samples
|
|
WO2018206737A1
|
|
Method for determination of members of the s100 family of calcium binding proteins by immunoturbidimetry
|
|
EP3499235A1
|
|
Method of measuring auto-antibodies in bodily fluids
|
|
EP3231453A1
|
|
Bone sialoprotein(bsp)-functionalised bone replacement bodies
|
|
AU2015306108A1
|
|
Medicament and apparatus for treating chronic kidney disease
|
|
AU2015220754A1
|
|
In vitro diagnostic and prognosis of contrast induced nephropathy (CIN) in patients undergoing coronary angiography
|
|
EP2946788A1
|
|
Method and composition for treating heart failure with preserved ejection fraction
|
|
EP2775306A1
|
|
Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
|
|
DE102012109457A1
|
|
Sample tubes for stool tests
|
|
WO2012136720A1
|
|
Analysing vitamin d metabolites in dried blood
|
|
EP2630964A1
|
|
Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
|
